Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Publication year range
1.
J Asthma ; 58(12): 1630-1636, 2021 12.
Article in English | MEDLINE | ID: mdl-32878518

ABSTRACT

OBJECTIVE: SARS-CoV-2 disease 2019 (COVID-19) is highly contagious and spreads rapidly. The application of preventive measures has proven to be the best strategy to minimize the number of patients and the dissemination of and deaths from COVID-19. The objective of this study was to determine the risk factors that limit the adherence of asthmatic patients to measures that prevent COVID-19 among residents of a region with a high risk of a COVID-19 outbreak. METHODS: Through a cross-sectional study, data from 2,372 participants aged 16-24 years were analyzed. To collect their information, a questionnaire was constructed using the Google Forms tool. Due to the prevention measures in place for COVID-19, the home quarantine of many people, and the lack of socialization, the questionnaire was distributed through email (Internet) and WhatsApp. A logistic regression analysis was performed to determine the relationship between the variables. RESULTS: The prevalence of asthma was 12.2%, and non-adherence to the guidelines for the prevention of COVID-19 was 53.1%. Approximately 30.8% of asthma patients did not comply with the basic prevention measures for COVID-19. The results of the logistic regression analysis showed that being male, active smoking, and believing that COVID-19 is not a more severe disease for people suffering from asthma than others were associated with non-adherence to the basic protection measures established in the guidelines for the prevention of COVID-19. CONCLUSIONS: It is important for health professionals to advise asthma patients to comply with the basic measures of protection against COVID-19 and timely use medications for asthma control.


Subject(s)
Asthma/complications , COVID-19/prevention & control , Guideline Adherence , SARS-CoV-2 , Adolescent , Asthma/drug therapy , Cross-Sectional Studies , Female , Humans , Logistic Models , Male , Risk Factors , Smoking/adverse effects , Young Adult
2.
Ars pharm ; 60(3): 169-176, jul.-sept. 2019. graf
Article in Spanish | IBECS | ID: ibc-186762

ABSTRACT

Objetivo: Se evaluó la actividad antimicrobiana de un extracto crudo de B. bassiana y dos fracciones del mismo contra bacterias de importancia clínica. Métodos: El micelio de cepa B. bassiana se remojó en metanol durante una semana, después se evaporo en un rotovapor a 45°C aplicando vacío. El extracto metanólico se hizo pasar con dos fases móviles para obtener una fracción A y B. La fracciones A, B y el extracto crudo C se evaluaron contra las cepas Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Salmonella tiphy, Pseudomonas aeruginosa y Acinetobacter baumannii con la técnica de microdilución en placa. Resultados: En la fracción A se observó un efecto antimicrobiano contra Salmonella typhi, Pseudomonas aeruginosa y Acinetobacter baumannii el crecimiento bacteriano alcanzó el 70, 60 y 83 % respectivamente. La fracción B causó un efecto antimicrobiano en Klebsiella pneumoniae, S. typhi, P. aeruginosa y A. baumannii con un crecimiento bacteriano del 62, 58, 41 y 7 % respectivamente. Y El extracto crudo no causó inhibición del crecimiento en A. baumannii, pero para el resto de la bacterias hubo un crecimiento del 56 al 88 %. Conclusiones: Beauveria bassiana es un hongo entomopatógeno que produce diferentes metabolitos con actividad insecticida, citotóxica, antifúngica, antibiótica y antiviral. Este es el primer estudio de los efectos antimicrobianos de un extracto metanólico del hongo entomopatógeno B. bassiana contra cepas bacterianas de importancia clínica


Objective: The antimicrobial activity of a crude extract of B. bassiana and two fractions thereof against clinically important bacteria was evaluated. Methods: The mycelium of strain B. bassiana was soaked in methanol for a week, then it was evaporated in a rotovap at 45 ° C applying a vacuum. The methanolic extract was passed through two mobile phases to obtain a fraction A and B. Fractions A, B and crude extract C were evaluated against the strains Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Salmonella tiphy, Pseudomonas aeruginosa and Acinetobacter baumannii with the plate microdilution technique. Results: In fraction A an antimicrobial effect against Salmonella typhi, Pseudomonas aeruginosa and Acinetobacter baumannii was observed, bacterial growth reached 70, 60 and 83% respectively. Fraction B caused an antimicrobial effect in Klebsiella pneumoniae, S. typhi, P. aeruginosa and A. baumannii with a bacterial growth of 62, 58, 41 and 7% respectively. And the crude extract did not cause growth inhibition in A. baumannii, but for the rest of the bacteria there was a growth of 56 to 88%. Conclusions: Beauveria bassiana is an entomopathogenic fungus that produces different metabolites with insecticidal, cytotoxic, antifungal, antibiotic and antiviral activity. This is the first study of the antimicrobial effects of a methanolic extract of the entomopathogenic fungus B. bassiana against bacterial strains of clinical importance


Subject(s)
Humans , Beauveria/chemistry , Cross Infection/microbiology , Anti-Bacterial Agents/pharmacology , Gram-Positive Bacteria/drug effects , Microbial Sensitivity Tests , Staphylococcus aureus/drug effects , Escherichia coli/drug effects , Klebsiella pneumoniae/drug effects , Salmonella typhi/drug effects , Pseudomonas aeruginosa/drug effects , Acinetobacter baumannii/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...